Maribavir
Maribavir is a pharmaceutical drug with 17 clinical trials. Currently 4 active trials ongoing. Historical success rate of 91.7%.
Success Metrics
Based on 11 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
3
Mid Stage
8
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
91.7%
11 of 12 finished
8.3%
1 ended early
4
trials recruiting
17
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies
A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection
A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants
Clinical Trials (17)
Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies
A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection
A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants
A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection
Maribavir Food-Effect Study in Healthy Adults Participants
A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients
Study of SHP620 (Maribavir) in Healthy Adults
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
Maribavir for Prevention of CMV After Stem Cell Transplants
The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients
All 17 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 17